EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.
Chen Y, Ouyang D, Wang Y, Pan Q, Zhao J, Chen H, Yang X, Tang Y, Wang Q, Li Y, He J, You JQ, Li Y, Xu C, Ren Y, Xie S, Li S, Lian J, Weng D, Xiang T, Xia JC.
Chen Y, et al. Among authors: li s, li y.
J Immunother Cancer. 2024 Jun 17;12(6):e008375. doi: 10.1136/jitc-2023-008375.
J Immunother Cancer. 2024.
PMID: 38886114
Free PMC article.